Female adnexal tumor of probable wolffian origin (FATWO) with recurrence 3 years postsurgery: C-kit gene analysis and a possibility of a new molecular targeted therapy

International Journal of Gynecological Pathology

Volumn 30, Issue 3, 2011, Pages 231-235

  Syriac, Susanna ^a   Durie, Nicole ^a   Kesterson, Joshua ^a   Lele, Shashrikant ^a   Mhawech Fauceglia, Paulette ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

C; FATWO; kit; Recurrence; Therapy

Indexed keywords

IMATINIB;

ABDOMINAL HYSTERECTOMY; ADNEXA DISEASE; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSULTATION; EXON; FEMALE; FEMALE ADNEXAL TUMOR OF PROBABLE WOLFFIAN ORIGIN; FEMALE ADREXAL TUMOR OF PROBABLE WOLFFIAN ORIGIN; FOLLOW UP; GENE AMPLIFICATION; GENETIC ANALYSIS; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE PERIOD; MOLECULARLY TARGETED THERAPY; ONCOGENE C KIT; PRIMARY TUMOR; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TREATMENT DURATION; TUMOR DIFFERENTIATION; UTERUS BLEEDING;

ADENOMA; ADNEXAL DISEASES; ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BROAD LIGAMENT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 79955075607     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3182005340     Document Type: Article

References (14)

1. Kariminejad MH, Scully RE. Female adnexal tumor of probable Wolffian origin. Cancer 1973;31:671-7.
2. Pedro TR, Judith KW, Anais M, et al. Wolffian duct tumors: case reports and review of the literature. Gynecol Oncol 2002;86:225-30.
3. Irena S, Jose LM, Pablo AB, et al. Metastatic female adenexal tumor of probable wolffian origin. Arch Pathol Lab Med 2000; 124:431-4.
4. Steed H, Oza A, Chapman WB, et al. Female adnexal tumor of probable wolffian origin: a clinicopathological case report and a possible new treatment. Int J Gynecol Cancer 2004;14:546-50. (Pubitemid 38747439)
5. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003; 9:3329-37. (Pubitemid 37082727)
6. Do I, Araujo E, Kalil R, et al. Protein expression of KIT and gene mutation of C-kit and PDGFRs in Ewing sarcomas. Pathol Res Pract 2007;203:127-34. (Pubitemid 46335570)
7. Deavers MT, Malpica A, Liu J, et al. Ovarian sex cordstromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol 2003;16: 584-90. (Pubitemid 36718440)
8. Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med 2008;132:402-23. (Pubitemid 351337535)
9. Devaouassoux-Shisheboran M, Sliver SA, Tavassoli FA. Wolffian adnexal tumor, so-called female adenexal tumor of probable origin (FATWO): immunohistochemistry evidence in support of a wolffian origin. Hum Pathol 1999;30: 856-63. (Pubitemid 29325794)
10. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol 2005;36:195-201. (Pubitemid 40313577)
11. Heatley MK. Is female adnexal tumour of probable wolffian origin a benign lesion? A systematic review of the English literature. Pathology 2009;41:645-8.
12. Harada O, Ota H, Takagi K, et al. Female adnexal tumor of probable wolffian origin: morphological, immunohistochemical and ultrastructural study with C-kit gene. Pathol Int 2006;56:95-100.
13. Merkelbach-Bruse S, Dietmaier W, Füzesi L, et al. Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. BMC Med Genet 2010;11:106-20.
14. Heinrich C, Griffith DJ, Druker BJ, et al. Inhibition of C-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32. (Pubitemid 30618049)